down arrow

Lipocine, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US53630X2036
USD
3.10
-0.15 (-4.62%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Lisata Therapeutics, Inc.
Oncternal Therapeutics, Inc.
Acorda Therapeutics, Inc.
Lipocine, Inc.
NanoViricides, Inc.
Virios Therapeutics, Inc.
Aprea Therapeutics, Inc.
Acurx Pharmaceuticals, Inc.
Azitra, Inc.
Galecto, Inc.
Hepion Pharmaceuticals, Inc.
Why is Lipocine, Inc. ?
1
Poor Management Efficiency with a low ROE of 1.45%
  • The company has been able to generate a Return on Equity (avg) of 1.45% signifying low profitability per unit of shareholders funds
2
The company has declared negative results in Mar'2025 after 4 consecutive positive quarters
  • NET SALES(HY) At USD 0.72 MM has Grown at -90.7%
  • PRE-TAX PROFIT(Q) At USD -2.21 MM has Fallen at -62.58%
  • NET PROFIT(Q) At USD -2.21 MM has Fallen at -62.56%
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -34.73%, its profits have risen by 10.7%
4
Falling Participation by Institutional Investors
  • Institutional investors have decreased their stake by -1.29% over the previous quarter and collectively hold 11.22% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
5
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -34.73% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Lipocine, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Lipocine, Inc.
-34.46%
-0.97
60.81%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
38.25%
EBIT Growth (5y)
10.32%
EBIT to Interest (avg)
-8.12
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.21
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
11.22%
ROCE (avg)
33.06%
ROE (avg)
1.45%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.88
EV to EBIT
0.42
EV to EBITDA
0.43
EV to Capital Employed
2.74
EV to Sales
-0.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
646.77%
ROE (Latest)
-28.27%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -7.72% (YoY

NET PROFIT(9M)

Higher at USD -2.29 MM

-21What is not working for the Company
NET SALES(HY)

At USD 0.72 MM has Grown at -90.7%

PRE-TAX PROFIT(Q)

At USD -2.21 MM has Fallen at -62.58%

NET PROFIT(Q)

At USD -2.21 MM has Fallen at -62.56%

CASH AND EQV(HY)

Lowest at USD 37.65 MM

Here's what is working for Lipocine, Inc.
Raw Material Cost
Fallen by -7.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Lipocine, Inc.
Net Sales
At USD 0.72 MM has Grown at -90.7%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Pre-Tax Profit
At USD -2.21 MM has Fallen at -62.58%
over average net sales of the previous four periods of USD -1.36 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -2.21 MM has Fallen at -62.56%
over average net sales of the previous four periods of USD -1.36 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Cash and Eqv
Lowest at USD 37.65 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."